Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides

US12097241B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Gene M. Dubowchik · Middlefield, US
• Olafur S. Gudmundsson · Princeton Colonial Park, US
• Xiaojun Han · Cheshire, US
• R. Michael Lawrence · Yardley, US
• Dasa Lipovsek · Pepperell, US
• Cort S. Madsen · Plainsboro, US
• Claudio Mapelli · Princeton, US
• Paul E. Morin · Pennington, US
• Michael C. Myers · Newtown, US

Key dates

• Filing date: Jan 11, 2022
• Grant date: Sep 24, 2024
• Expiry date: Jul 28, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P9/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.